Research Innovation

Innovation highlights

  • Discoveries by RWJMS investigators Peter Lobel, Ph.D. and David Sleat, Ph.D. led to the first FDA-approved treatment for a fatal degenerative disease in children for which there is no other approved treatment option…read more
  • Patent for a new drug to treat deadly infections with antibiotic-resistant bacteria (MRSA, methicillin-resistant Sta[phylococcus aureus) … read more
  • Two patents awarded novel drug and target fo rtretmant of Parkinson's Disease, to lslow brain degeneration and control symptoms … read more

Browse our patents & licenses

Start-up companies spun-off from faculty inventions

Featured Entrepreneurship

TAXIS Pharmaceuticals, a Rutgers start-up company co-founded by Daniel Pilch, PhD (Associate Professor of Pharmacology at Robert Wood Johnson Medical School) together with Edmond Lavoie (Professor and Chair, Medicinal Chemistry in the School of Pharmacy) receed FDA approval to test TXA709, a new drug specifically designed to treat methicillinā€resistant Staphylococcus aureus (MRSA) that annually kills approximately 19,000 individuals in the US. Taxis Pharmaceuticals Inc. was featured as “Emerging company in the spotlight” by BioNJ, highlighting their progress on behalf of patients and the impact on the New Jersey Life sciences ecosystem. TAXIS mission is to discover drugs to address the antibiotic resistance crisis and that will change the treatment landscape. Photo